Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.
Stock data | 2024 | Change |
---|---|---|
Price | $2.87 | N/A |
Market Cap | $358.66M | N/A |
Shares Outstanding | 124.97M | N/A |
Employees | 160.00 | N/A |